Small Molecule Drug Discovery Screen Using AstraZeneca Facilities

This funding opportunity supports researchers in conducting high-throughput screening to identify potential small molecule drug candidates. Successful applicants will access AstraZeneca's extensive compound library and advanced screening robotics platform at no cost. Up to four projects will be funded annually, with individual awards up to £270,000 and typical project duration of 15 months. This program is designed for academic institutions, biotech companies, and research organizations seeking to accelerate early-stage drug discovery. Eligible projects should demonstrate clear scientific merit and potential for developing new therapeutic compounds. The screening services eliminate significant capital and operational barriers to drug discovery research.